Method for producing influenza HA split vaccine
View Patent ↗Provided is a method for producing an influenza HA split vaccine which produces an antibody that binds to a HA stem region of influenza, the HA stem region being less likely to cause antigenic variation, An influenza HA split vaccine is subjected to an acidic treatment. Through the acidic treatment, an influenza HA split vaccine which produces an antibody that binds to a LAH of the HA stem region is obtained. This influenza HA split vaccine has an excellent protective ability against infection of other influenza viruses of different antigenicity.
1. A method for producing an influenza haemagglutinin (HA) split vaccine which produces an antibody that binds to a long alpha helix (LAH) of a HA stem region, the method comprising:
treating influenza virus particles with ether to obtain an influenza HA split vaccine; and
subjecting said influenza HA split vaccine, which has not undergone a formalin treatment, to an acidic treatment.
2. A method for producing an influenza HA split vaccine which produces an antibody that binds to a LAH of a HA stem region, the method comprising:
treating influenza virus particles with ether to obtain an influenza HA split vaccine; and
subjecting an influenza HA split vaccine, which has not undergone a formalin treatment, to an acidic treatment, and
thereafter, subjecting the influenza HA split vaccine to a formalin treatment.
3. A method for producing an influenza HA split vaccine which produces an antibody that binds to a LAH of a HA stem region and which is effective against an influenza virus that causes antigenic variation, the method comprising:
treating influenza virus particles with ether to obtain an influenza HA split vaccine; and
subjecting said influenza HA split vaccine, which has not undergone a formalin treatment, to an acidic treatment.
4. The method of claim 1 , wherein the acidic treatment is performed at a pH of 4.4 to 5.8.
5. The method of claim 1 , wherein the influenza HA split vaccine is of type H3N2 or type H1N1.
6. The method of claim 1 , wherein the acidic treatment is performed at a pH of 4.4 to 5.8.
7. The method of claim 2 , wherein the acidic treatment is performed at a pH of 4.4 to 5.8.
8. The method of claim 3 , wherein the acidic treatment is performed at a pH of 4.4 to 5.8.
9. The method of claim 1 , wherein the influenza HA split vaccine is of type H3N2 or type H1N1.
10. The method of claim 2 , wherein the influenza HA split vaccine is of type H3N2 or type H1N1.
11. The method of claim 3 , wherein the influenza HA split vaccine is of type H3N2 or type H1N1.
12. The method of claim 1 , wherein the influenza HA split vaccine is an influenza HA split vaccine of a single HA subtype.
13. The method of claim 2 , wherein the influenza HA split vaccine is an influenza HA split vaccine of a single HA subtype.
14. The method of claim 3 , wherein the influenza HA split vaccine is an influenza HA split vaccine of a single HA subtype.
15. The method of claim 1 , the method including: mixing two or more of influenza HA split vaccine antigens, each of which is produced by subjecting an influenza HA split vaccine of a single subtype to an acidic treatment.
16. The method of claim 2 , the method including: mixing two or more of influenza HA split vaccine antigens, each of which is produced by subjecting an influenza HA split vaccine of a single subtype to an acidic treatment.
17. The method of claim 3 , the method including: mixing two or more of influenza HA split vaccine antigens, each of which is produced by subjecting an influenza HA split vaccine of a single subtype to an acidic treatment.
18. The method of claim 1 , wherein the influenza HA split vaccine which produces an antibody that binds to a LAH of a HA stem region is effective against an influenza virus that causes antigenic variation.
19. The method of claim 2 , wherein the influenza HA split vaccine which produces an antibody that binds to a LAH of a HA stem region is effective against an influenza virus that causes antigenic variation.
20. The method of claim 1 , wherein said acid treatment changes the structure of the influenza HA split vaccine to a membrane fusion-type HA split vaccine, thus exposing the HA stem region.
21. The method of claim 1 , wherein said influenza HA split vaccine produces a LAH binding antibody titer being at least 3-fold higher compared to an influenza HA split vaccine obtained without the acidic treatment.
22. The method of claim 20 , wherein said influenza HA split vaccine produces a LAH binding antibody titer being at least 3-fold higher compared to an influenza HA split vaccine obtained without the acidic treatment.
23. The method of claim 2 , wherein said acid treatment changes the structure of the influenza HA split vaccine to a membrane fusion-type HA split vaccine, thus exposing the HA stem region.
24. The method of claim 2 , wherein said influenza HA split vaccine produces a LAH binding antibody titer being at least 3-fold higher compared to an influenza HA split vaccine obtained without the acidic treatment.
25. The method of claim 23 , wherein said influenza HA split vaccine produces a LAH binding antibody titer being at least 3-fold higher compared to an influenza HA split vaccine obtained without the acidic treatment.
26. The method of claim 3 , wherein said acid treatment changes the structure of the influenza HA split vaccine to a membrane fusion-type HA split vaccine, thus exposing the HA stem region.
27. The method of claim 3 , wherein said influenza HA split vaccine produces a LAH binding antibody titer being at least 3-fold higher compared to an influenza HA split vaccine obtained without the acidic treatment.
28. The method of claim 26 , wherein said influenza HA split vaccine produces a LAH binding antibody titer being at least 3-fold higher compared to an influenza HA split vaccine obtained without the acidic treatment.